Search Technologies

Showing 1-3 of 3 results found

Use of a Modified Adaptor Molecule LAT to Improve Immunotherapy for Cancer and Other Diseases

Researchers at the NCI have developed a method of improving the immune response in cancer immunotherapy by exploiting in the role of the Linker Adapted for T-Cell Signaling (LAT) molecule. The LAT molecular can enhance signaling through TCRs, thus, improving a patient’s own immune response to cancer or infectious diseases.

Therapeutics

Tempol as a Therapeutic to Treat Covid-19 Via Inhibition of Viral Replication

The National Cancer Institute (NCI) and the National Institute of Child Health and Human Development (NICHD) seek research co-development partners and/or licensees for an antiviral treatment that can target SARS-Cov-2 replication in Covid-19 patients.

Therapeutics

Novel Fusion Proteins for HIV Vaccine

The National Cancer Institute’s Cancer and Inflammation Program seeks parties to license gp120 and CD4-induced antibody fusion proteins for use in an HIV vaccine.

Research Tools

You are here

Product Type

Development Stage

Therapeutic Area

Institutes and Centers

Search Technologies

Use of a Modified Adaptor Molecule LAT to Improve Immunotherapy for Cancer and Other Diseases

Tempol as a Therapeutic to Treat Covid-19 Via Inhibition of Viral Replication

Novel Fusion Proteins for HIV Vaccine